- Home
- LSTA vs CURX Comparison
LSTA vs CURX Comparison
Compare LSTA & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTA | CURX |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 14.5M |
| IPO Year | 2000 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LSTA | CURX |
|---|---|---|
| Price | $5.00 | $0.45 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 48.8K | ★ 275.6K |
| Earning Date | 05-07-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $1.81 | $0.26 |
| 52 Week High | $5.07 | $9.18 |
Technical Indicators
Market Signals| Indicator | LSTA | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 66.67 | 48.67 |
| Support Level | $5.00 | $0.38 |
| Resistance Level | $5.04 | $0.52 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 30.00 | 25.14 |
Price Performance
Historical ComparisonAbout LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.